Position in NAMS
as of Jun 30, 2026
· filed Jul 20, 2026
Position Value
$101
+$5 QoQ
Shares Held
3
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#197
of 198 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NAMS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026IFP Advisors, Inc holds $55,990,065 across 216 Biotechnology names. NAMS ranks #184 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AXSM |
Axsome Therapeutics, Inc.
|
62,273 | $15,242,562 | |
| 2 | TGTX |
Tg Therapeutics, Inc.
|
209,318 | $11,499,930 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
34,193 | $8,239,487 | |
| 4 | AUPH |
Aurinia Pharmaceuticals Inc.
|
361,634 | $6,136,928 | |
| 5 | VKTX |
Viking Therapeutics, Inc.
|
61,616 | $2,403,640 | |
| 6 | EXEL |
Exelixis, Inc.
|
43,101 | $2,345,125 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,968 | $1,474,294 | |
| 8 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,352 | $843,026 |
All Filings in NAMS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $101 | 3 | Shares | Sole | 2026-07-20 | |
| 2026-03-31 | $96 | 3 | Shares | Sole | 2026-04-13 | |
| 2025-12-31 | $105 | 3 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $85 | 3 | Shares | Sole | 2026-02-06 | |
| 2025-06-30 | $54 | 3 | Shares | Sole | 2025-07-24 | |
| 2025-03-31 | $20 | 1 | Shares | Sole | 2025-05-05 | |
| 2024-12-31 | $25 | 1 | Shares | Sole | 2025-02-04 | |
| No filing history on record for this holder in this stock. | ||||||